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Although over 85% of osteogenesis imperfecta (OI) cases 
are associated with mutations in the procollagen type I 
genes (COL1A1 or COL1A2), no hot spots for the muta-
tions were associated with particular clinical phenotypes. 
Eight patients that were studied here, diagnosed with 
OI by clinical standards, are from the Polish population 
with no ethnic background indicated. Previously unpub-
lished mutations were found in six out of those eight pa-
tients. Genotypes for polymorphisms (Sp1 – rs1800012 
and PvuII – rs412777), linked to bone formation and 
metabolism were determined. Mutations were found in 
exons 2, 22, 50 and in introns 13 and 51 of the COL1A1 
gene. In COL1A2, one mutation was identified in exon 
22. Deletion type mutations in COL1A1 that resulted in 
OI type I had no effect  on collagen type I secretion, nor 
on its intracellular accumulation. Also, a single base sub-
stitution in I13 (c.904-9 G>T) was associated with the OI 
type I. The OI type III was associated with a single base 
change in I51 of COL1A1, possibly causing an exon skip-
ping. Also, a missense mutation in COL1A2 changing 
Gly→Cys in the central part of the triple helical domain 
of the collagen type I molecule caused OI type III. It af-
fected secretion of the heterotrimeric form of procolla-
gen type I. However, no intracellular accumulation of 
procollagen chains could be detected. Mutation in CO-
L1A2 affected its incorporation into procollagen type I. 
The results obtained shall help in genetic counseling of 
OI patients and provide a rational support for making in-
formed, life important decisions by them and their fami-
lies.
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INTRODUCTION
Osteogenesis imperfecta (OI) is a heterogenic, connective 
tissue related disorder, manifested by bone fragility, with 
autosomal dominant, rarely recessive, inheritance and 
1/104 to 1/3 × 104 prevalence (Roughley et al., 2003; Tar-
nowski & Sieron, 2008; Forlino et al., 2011; van Dijk & 
Sillence, 2014). The OI patients have poor quality of life 
due to frequent bone fractures, resulting from minimal 
trauma during regular daily activities. International No-
menclature Group for Constitutional Disorders of the 
Skeleton has proposed in 2009 classification of OI types 
based on radiological and clinical criteria (Sillence & Ri-
moin, 1978; van Dijk et al., 2011; Warman et al., 2011). 
At present, there are 15 types of OI in OMIM. In this 
work we focused on patients with OI types I and III. 
The type I is the least severe (blue sclera, low bone frac-
ture frequency and slight or no skeletal deformities) (Sil-
lence & Rimoin, 1978). Type III is an opposite progres-
sive dominant form (Sillence & Rimoin, 1978; Sillence et 
al., 1979; Warman et al., 2011). In type III, in most se-
vere cases the patients may develop respiratory problems 
leading eventually to death. Those patients which survive 
present severe health problems affecting their life quality 
(Tarnowski & Sieron, 2008; van Dijk & Sillence, 2014). 
About 90% of OI cases are due to causative variants 
in COL1A1 and COL1A2 genes resulting in abnormal 
collagen I fibrils formation (Forlino et al., 2011). The 
remaining 10% associate with recessive variants of 19 
known or yet to be discovered genes (Dalgleish, 1997; 
Dalgleish, 1998; Galicka, 2012). Heterogeneity of OI 
symptoms and causative gene variants imposes complex 
modifying factors: genetic, epigenetic and environmental. 
Polymorphisms in COL1A1 and COL1A2 are among 
the factors influencing individuals to cope differently 
with mutational effects at the molecular level. Recently, 
more than 50 polymorphisms were identified in both 
the genes in the Indian population (Stephen et al., 2014). 
Two most common polymorphisms associated with di-
minished bone mineralization and lower resistances to 
trauma causing fractures are Sp1 in COL1A1 (Grant 
et al., 1996; Dehghan & Pourahmad-Jaktaji, 2015), and 
PvuII at position g.23065 in exon 25 of COL1A2. Sp1 is 
linked to low bone mineral density (BMD), osteoporo-
sis, higher risk of bisphosphonate induced osteonecrosis 
of the jaw and an elevated risk of developing inguinal 
hernias (Katz et al., 2011; Kurt-Sirin et al., 2014; Sezer 
et al., 2014). The PvuII polymorphism is linked to vari-
ations in BMD, e.g. in pre-pubertal girls a transversion 
A→C in g.23065 („p” allele) is strongly correlated with 
fracture frequency and variable bone strength parameters 
(Blades et al., 2010). In a dedicated database, Osteo-
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genesis Imperfecta Variant Database there are 86 total 
public entries for COL1A1 and 58 total public entries 
for COL1A2 for Caucasian – Polish ethnic origin. No 
extensive comparison of both SNPs’ frequency in nei-
ther Polish nor in general Caucasian population is avail-
able. Therefore, the two polymorphisms already linked 
to bone density but not to OI, were also analyzed along 
with the mutations in procollagen type I encoding genes. 
Therefore, the aim of this work was to verify if there is 
a link between the clinical diagnosis of the OI type, the 
mutation detected in the affected patient and the indi-
vidual status for the two SNPs, Sp1 and PvuII.
MATERIALS AND METHODS
Patient data. Clinical characteristics were collected by 
physician specialists in medical genetics who also co-au-
thor this report. The patient’s medical and family genetic 
histories were prepared based on “Clinical check list” 
according to EMQN guidelines for the diagnosis of OI 
patient, which for our patients was translated to Polish.
Methods
Materials. DNA was isolated from blood samples or 
skin fibroblasts obtained from five females (F) and three 
males (M) diagnosed with OI types I or III (Table 1). 
The study protocol was approved by the Bioethical 
Committee of Medical University of Silesia in Katowice, 
Poland (Approval No. KBET/356/B/2003). 
Isolation and purification of genomic DNA. DNA 
isolation from blood or skin fibroblasts was conducted 
using DNA purification kit “Blood Mini” (A&A Bio-
technology, Poland). 
Conditions for amplifying and DNA sequencing 
PCRs. The PCRs were conducted using FastStartTaq 
DNA Polymerase kit (Roche, Germany) and the ampli-
cons were verified.  The reaction mixtures were prepared 
as described elsewhere (Witecka et al., 2008; Majka et al., 
2013). The amplicons were verified following electropho-
resis in 1% agarose gel using 5 µl of the obtained PCR 
products.
Sanger’s enzymatic method was used for DNA se-
quencing, therefore, 20 ng of each purified PCR prod-
uct was mixed with 5 pM of the appropriate sequencing 
primer, for SpI: 5’-TCT-GGG-GAG-CCG-CTA-GCG-
CGG-3’; for PvuII: 5’-TTT-CAT-CCG-TGG-CAG-CAT-
CAT-AAG-C-3’ with Big Dye Terminator v.3.1. The 
sequencing PCR was conducted according to a protocol 
described elsewhere (Witecka et al., 2008; Majka et al., 
2013).
Purified PCR sequencing products were analyzed us-
ing genetic analyzer ABI 3130xl (Applied Biosystems, 
USA) and the sequences were verified using Chromas 
Lite 2.01 and Nucleotide Blast (NCBI) software online 
to reference sequences NG_007400.1 for COL1A1 and 
NG_007405.1 for COL1A2.
Fibroblast culture, procollagen type I separation 
and SDS PAGE/western blot analysis. Fibroblast cells 
were obtained from skin biopsies as previously described 
(Witecka et al., 2008). The cells were cultured in T75 (75 
cm2) culture flasks in Dulbecco’s Modified Eagle’s Me-
dium supplemented with glucose (4.5 g/L), fetal calf se-
rum (10%), penicillin (10 000 IU/mL), streptomycin (10 
mg/L), amphotericin B (25 mg/mL) (all reagents from 
PAA Laboratories, GmbH). The cells were cultured un-
til reaching 80% of confluence. Then the cell monolayer 
was washed twice with sterile PBS and supplemented 
with medium free of antibiotics and serum. Following 
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subsequent 48 hours, the medium was harvested, supple-
mented with the mixture of protease inhibitors in Sigma-
Fast Protease Inhibitor Coctail Tablet (Sigma, Germany) 
and divided in to two parts. One part was mixed with 
0.25 volume of 5 × storage buffer to provide a final 
concentration of 25 mM EDTA and 0.04% NaN3 in 0.1 
M Tris/HCl buffer (pH 7.4). The samples were filtered 
through a 1.6 mm glass-fiber filter (Millipore). Proteins 
from one part were precipitated overnight at 4°C with 
176 mg/ml (NH4)2SO4. The precipitate was separated by 
centrifugation at 15 000 × g for 30 minutes.
The other part of the medium was precipitated with 
30% polyethylene glycol (PEG) at its final concentra-
tion of 5%. The precipitated proteins were recovered 
by centrifugation as from the previous part and both 
parts were stored at –20°C until their further analysis by 
SDS PAGE, followed by electro-transfer to Immobilon 
Transfer Membrane (Millipore, USA) and western blot 
analysis. 
Simultaneously, fibroblasts used for procollagen pro-
duction were detached using 0.25% trypsin in 1 mM 
EDTA (PAA Laboratories, GmbH). The trypsin and 
EDTA were neutralized with an equal volume of serum 
free culture medium and the fibroblast numbers were de-
termined in samples pre-stained with Trypan Blue Dye, 
(0.4%) using TC20 Automated Cell Counter (Bio-Rad). 
Cold lysis solution (0.1% NP40 and 10µg/ml DNase I 
in PBS) was used at the volume enabling to obtain the 
fibroblast density of 20 000 cells per 1 µL. 
Proteins precipitated with ammonium sulfate were 
solubilized in a storage buffer (0.4 M NaCl, 0.1 M TRIS-
HCl, 0.025 M EDTA, 0.04% NaN3; pH 7.4). The pro-
teins, precipitated with PEG, were solubilized in 1 x SB 
buffer (0.25 M Tris-HCl, pH 6.8; 50% glycerol, 5% SDS, 
0.05% bromophenol blue, 0.1% β-mercaptoethanol) in a 
volume equal to the volume of solution used for lysis of 
fibroblasts recovered from the culture (all reagents were 
purchased from Sigma-Aldrich Co.). Total protein con-
centrations were determined using a spectrophotometer 
(Nanodrop2000, ThermoScientific, USA) at 214 nm and 
280 nm wavelengths. The same amounts of total pro-
teins were analyzed for presence of procollagen type I 
by Western blotting, using Monoclonal Anti-collagen 
type I produced in mice (#C2456, Sigma).
RESULTS
Patients’ characteristics
The patient’s clinical phenotypes are summarized in 
Table 1. Six patients were clinically diagnosed as type I 
OI and two as type III. The initial diagnoses of five pa-
tients were without specification of the type of OI due 
to inconsistent examination protocols in different medi-
cal institutions (Table 1). In such situations, further ex-
aminations and additional medical tests were performed 
for complete clinical diagnosis of the type of OI (Ta-
ble  2). For the three patients with OI type recognized 
initially,  had their clinical diagnosis confirmed. Finally, 
four women were diagnosed with type I and one female 
was diagnosed with type III. In addition, the males had 
their OI confirmed as type I and III. Our observations 
indicate that a full panel of recommended clinical tests 
and examinations is required for complete diagnosis of 
the OI type. Particularly, X-rays of skeleton that in our 
study were available only for some of the patients, are 
necessary for correct diagnosis of the OI type (Fig. S1 at 
www.actabp.pl). 
New mutations detected in COL1A1 and COL1A2 DNA 
sequences
An analysis of chromatograms obtained by sequencing 
of the PCR products revealed six heterozygous sequence 
changes (Table 2). Subsequent alignment of the sequenc-
es with respective reference sequences for COL1A1 and 
COL1A2 revealed three mutations in COL1A1 gene in 
four females and in one male, and two other mutations 
in two males (Table 2). In the COL1A2 gene, one previ-
ously unreported mutation was found (Table 2). At least 
one, but possibly three mutations, two in COL1A1 and 
one in COL1A2 genes, were inherited based on the fam-
ily genetic history, whereas other mutations were detect-
ed in unrelated patients, without a family genetic history 
Table 2. Summary of clinical diagnosis and DNA sequencing results of OI patients participating in this study.
Order 
No.
Patient’s 
No./Gen-
der
Confir-
med type 
of OI
Mutated 
gene
Location of 
mutation
(E-exon; I-in-
tron)
Position in 
cDNA
Mutation at 
protein level
Genotype 
of Sp1  po-
lymorphism 
(rs1800012)
Genotype of Pvu-
II  polymorphism 
(rs412777)
1 91-D/F I COL1A1 E2 c.231delG p.Thr78Pro/fs*76 SS (G/G) Pp (A/C)
2 G9/M I COL1A1 I13 c.904-9 G>T not applicable SS (G/G) PP (A/A)
3 55/F I COL1A1 E22 c.1503delT p.Ala502Leu/fs*5 SS (G/G) Pp (A/C)
4 56/F I COL1A1 E22 c.1503delT p.Ala502Leu/fs*5 SS (G/G) Pp (A/C)
5 57/M I COL1A1 E22 c.1503delT p.Ala502Leu/fs*5 SS (G/G) Pp (A/C)
6 73/F I COL1A1 E50 c.[3881A>T; 3882_3891 del
p.Glu1294Val/
fs*32 SS (G/G) pp (C/C)
7 137/M III COL1A1 I51
c.4248+1G>A/
possible exon 
skipping
not applicable SS (G/G) PP (A/A)
8 19/F III COL1A2 E22 c.1207G>T p.Gly403Cys SS (G/G) Pp (A/C)
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(Table 1). All of the mutations affected the coding se-
quences. In COL1A1, three mutations were single nucle-
otide deletions with subsequent frame shifts resulting in 
nonsense codons located 5, 32 or 76 nucleotides down-
stream of the deletion. Additionally, in one female pa-
tient the deletion was next to another missense mutation 
(73/F). In two patients, two mutations, both changing 
G>T/A, occurred in introns. In COL1A2, the mutation 
was a missense mutation changing glycine to cysteine in 
a female with type III OI. 
The polymorphisms detected in collagen encoding 
genes
An analysis of sequencing chromatograms of the re-
spective polymorphism sites in the genomic DNA, re-
vealed that all of the patients were homozygous for wild 
type Sp1 polymorphism in the COL1A1 gene (Fig. 1 and 
Table 2). The PvuII polymorphism was detected in all 
three possible combinations (Fig. 1 and Table 2). Three 
females, two with type I and one with type III OI, were 
heterozygous for the PvuII polymorphism. Two males, 
one with type I and the other one with type III OI, were 
homozygous for the wild type (PP) genotype. The type 
I OI 73/F patient with a missense mutation followed by 
an immediate single base deletion and subsequent non-
sense codon was homozygous for mutated allele of the 
PvuII polymorphism (pp). It is surprising that a single 
nucleotide deletion accompanied by homozygous “pp” 
polymorphism resulted in just a mild clinical phenotype. 
Effect of the mutations on secretion of procollagen 
type I
The analysis of secreted procollagen type I from fi-
broblasts of three patients, two with OI type I and one 
with OI type III, revealed that in case of mutations in 
COL1A1 no retention of procollagen alpha chains in the 
cells could be detected (right panel in Fig. 2A). How-
ever, alpha 2 chain could be detected by western blot 
analysis only as a fine band in precipitates from the cul-
ture medium obtained from fibroblasts of patients 91-
D/F (OI type I) and 19/F (OI type III) (left panel in 
Fig. 2A). Procollagen alpha chains identified in the fi-
broblast culture medium of 73/F the patient (OI type I) 
migrated faster than the procollagen chains from control 
fibroblasts (lane marked 73/F in the left panel of WB 
blot in Fig. 2A). This resulted from a mutation in exon 
50 of COL1A1, c.3881A>T. The mutation changed Glu 
at position 1294 to Val (Table 2). There was also a dele-
tion of 9 nucleotides from position 3882 to 3891 (Ta-
ble 2), which resulted in frame shift and a subsequent 
stop codon following the next 32 codons. In the culture 
medium collected from fibroblasts of the 19/F patient 
(OI type III) carrying a mutation in exon 22 of COL1A2 
(c.1207G>T) which changes  one codon  (Gly403Cys), 
Figure 1. Selected representative chromatograms of the sequence around the Sp1 and PvuII polymorphic sites. 
Polymorphism position g.6252 in COL1A1 in patients with homozygous wild type (upper left panel). Polymorphism position g.23065 in 
COL1A2 in patients with: homozygous wild type (upper right), heterozygous (bottom left) and homozygous recessive (bottom right). 
Arrows point to the polymorphic sites.
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only a very fine band corresponding to procollagen type 
I alpha2 chain was detected, whereas pro-alpha1 chain 
was represented by a much stronger band, indicating the 
ratio of α1: α2 to be higher than 2:1. 
Although  fibroblasts from the 91-D/F patient with 
a mutation in exon 2 (c.231delG) causing a frame shift 
(p.Thr78Pro), and a stop codon 76 codons downstream 
of the change, secreted the heterotrimeric procollagen 
type I, the pro-α2 chain was present in the culture me-
dium at a lower amount than in the control (Fig. 2A). 
An analysis of proteins in lysates of cultured fibro-
blasts following SDS/PAGE and WB did not reveal 
intracellular retention of pro-alpha chains in any of the 
analyzed fibroblasts. However, some non-specific cross-
reaction of the anti-human type I procollagen antibodies 
was detected in lysates from all fibroblasts, including the 
control ones (Right panel in Fig. 2A). It is possible that 
the cross reaction of the antibodies was due to the pres-
ence of products of partial degradation of the type I pr-
ocollagen chains. Poor detection of procollagen type I in 
the lysates of fibroblasts from patients 19/F and 91-D/F 
needs to be further investigated (Fig. 2A, right panel). In 
addition, problems with determination of thermal stabil-
ity of procollagen type I in all three cases were probably 
due to the poor protein yields from the culture medium 
of the fibroblasts obtained from the OI patients (data 
not shown).
DISCUSSION
Mutation locations analyzed in this paper did not 
point directly to type of OI. The resulting changes in 
the encoded amino acids are not sufficient for predicting 
how severe the disorder will be. The consistence of the 
glycine codon changes to the cysteine codon (at position 
403 in patient 19/F) correlates with commonly accepted 
Figure 2. Effect of detected mutations on procollagen type I production, secretion and potential properties of the proteins. 
(A) detection of procollagen alpha chains in the fibroblasts and their culture medium. (B) Alignment of amino acid sequences around 
the mutations (underlined capital letter) and the nonsense codon (*). (C) Location of the Gly403Cys mutation (highlighted in red) in the 
type I procollagen α2 chain and potential sites of interaction with interleukin 2, decorin and α2β1 integrin. Boxed are Gly-Xxx-Hyp-Pro 
sequences potentially involved in triple helix stabilization. The numbering of nucleotides and amino acids are for sequences in cDNA 
encoding a triple helical domain in two α1 and one α2 chains of procollagen type I, respectively. Symbols in (A) M, purified human pro-
collagen type; C, proteins recovered from the culture medium of control skin fibroblasts (left panel) or the lysed fibroblasts (right pan-
el); 73/F, proteins recovered from the culture medium of fibroblasts obtained from the 73/F patient (left panel) or the lysed fibroblasts 
(right panel); 19/F, proteins recovered from the culture medium of fibroblasts obtained from the 19/F patient (left panel) or the lysed 
fibroblasts (right panel); 91-D/F, proteins recovered from the culture medium of fibroblasts obtained from the 91-D/F patient (left pan-
el) or the lysed fibroblasts (right panel); Pro α1(I), alpha 1 chain of procollagen type I; Pro α2(I), alpha 2 chain of procollagen type I; ?, 
cross reaction of the anti-human procollagen type I antibodies with unidentified proteins or possible products of crosslinking of procol-
lagen type I alpha chains (left panel) or intracellular degradation of procollagen type I alpha chains (right panel); an asterisk, indicates 
position of migration of intracellular alpha 1 chain of procollagen type I. Western blot pictures are representative of experiments done in 
quadruplicate. The cultures of fibroblasts for procollagen analyses were repeated and the western blots from each experiment were also 
done in duplicate.
Vol. 65       85Clinical report on new OI linked mutations
Gly to Xxx substitutions resulting in a more severe type 
III or a lethal type II of OI (Byers et al., 1991; Roughley 
et al., 2003;). In addition, the possible exon skipping ef-
fect of I51 mutation  at the 4248+1 position could ex-
plain the more severe type III phenotype manifested by 
a tremendous number of bone fractures (170 incidents 
within 26 years).
Presence of both “PP” and “SS” genotypes was linked 
to a two-fold lower risk of long bone fracture in chil-
dren (Mann et al., 2001; Blades et al., 2010; Kurt-Sirin 
et al., 2014). The homozygous wild type status for both 
polymorphisms did lower the risk of bone fractures by 
half. Results reported by others revealed that the pres-
ence of at least one copy of the “s” allele of Sp1 poly-
morphism in COL1A1 gene increased the risk of long 
bone fractures prior to maturation by three-folds also 
in healthy children (Pace et al., 2008). No such corre-
lation was found in dual energy X-ray absorptiometry 
results (DXA – means of measuring bone mineral den-
sity) among those children. Here, we did not find such 
a correlation probably because all of the patients were 
homozygous for wild type allele of the Sp1 polymor-
phism. The genotypic status for PvuII polymorphism had 
no effect on bone fractures in patients with OI type III 
(Table 1).
Faster migration of procollagen alpha chains in patient 
73 could be a result of weaker posttranslational modifica-
tion, probably glycosylation, due to the C-propeptide of 
pro-α1 chain shortened 139 amino acids (Top alignment 
in Fig. 2B). In addition, it has been reported previously 
that correct proα2(I) C-propeptide is critical for procol-
lagen assembly (Suuriniemi et al., 2006). Therefore, one 
could speculate that the disturbance in the registry of the 
three procollagen chains due to different lengths of the 
C-propetides from the three alpha chains, could lead to 
procollagen suicide. However, the non-mutated chains 
could be abnormally under-hydroxylated as an effect of 
insufficient amount of newly synthetized type I procolla-
gen. Therefore, it could be processed faster through the 
ER and Golgi apparatus and more quickly secreted. 
Disturbed ratio of procollagen chains in patient 19/F 
could be explained by shortage of the α2 chain, as α1 
homo-trimer was secreted along with trace amounts of 
the hetero-trimer (Fig. 2A). The mutation is located in 
the region flanked by Gly-Xxx-Hyp triplets in both, α1 
and α2 chains (Fig. 2C). This fragment also contains 
amino acids forming sites for interactions with interleu-
kin 2, decorin and α2β1 integrin (Di Lullo et al., 2002) 
(Fig. 2C). Therefore, substitution of a small glycine resi-
due by a larger cysteine in the pro-α2(I) might disturb 
the structure of the triple-helix,  decrease its stability and 
disturb binding sites for the above listed factors.  
In case of patient 91-D/F it is possible that this ex-
tremely short polypeptide, containing just 152 amino ac-
ids due to a stop codon (bottom sequence in Fig. 2B), 
and mutated pro-α1 chain could be degraded, therefore, 
causing insufficient amount of procollagen type I to be 
secreted. 
Results obtained by detection of mutations in genes 
encoding procollagen type I in patients diagnosed with 
either type I or III OI revealed that the causative mu-
tations might occur anywhere in both genes. The clini-
cal outcome resulting from these mutations is complex 
and the severity is difficult to predict based only on the 
type and location of the mutation, particularly when the 
mutation is dominant. Although recommendation for OI 
diagnosis based on a clinical exam and verified by  DNA 
gene sequencing, but without protein analysis, is suffi-
cient for clinical treatment, it seems to be insufficient for 
genetic counseling of both, the patient and the patient’s 
parents. Therefore, more research is needed on effects 
of pathogenic mutations on cell biology.
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